226 related articles for article (PubMed ID: 32430662)
1. The brave new world of endometrial cancer : Future implications for adjuvant treatment decisions.
Marnitz S; Waltar T; Köhler C; Mustea A; Schömig-Markiefka B
Strahlenther Onkol; 2020 Nov; 196(11):963-972. PubMed ID: 32430662
[TBL] [Abstract][Full Text] [Related]
2. Identification of
Beinse G; Rance B; Just PA; Izac B; Letourneur F; Saidu NEB; Chouzenoux S; Nicco C; Goldwasser F; Batteux F; Durdux C; Chapron C; Pasmant E; Leroy K; Alexandre J; Borghese B
Int J Gynecol Cancer; 2020 May; 30(5):640-647. PubMed ID: 32169874
[TBL] [Abstract][Full Text] [Related]
3. Classification of Endometrial Carcinoma: New Perspectives Beyond Morphology.
Akhtar M; Al Hyassat S; Elaiwy O; Rashid S; Al-Nabet ADMH
Adv Anat Pathol; 2019 Nov; 26(6):421-427. PubMed ID: 31567131
[TBL] [Abstract][Full Text] [Related]
4. Histopathological features of endometrial carcinomas associated with POLE mutations: implications for decisions about adjuvant therapy.
Bakhsh S; Kinloch M; Hoang LN; Soslow RA; Köbel M; Lee CH; McAlpine JN; McConechy MK; Gilks CB
Histopathology; 2016 May; 68(6):916-24. PubMed ID: 26416160
[TBL] [Abstract][Full Text] [Related]
5. The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses.
McAlpine J; Leon-Castillo A; Bosse T
J Pathol; 2018 Apr; 244(5):538-549. PubMed ID: 29344951
[TBL] [Abstract][Full Text] [Related]
6. Mismatch repair deficiency as a predictive marker for response to adjuvant radiotherapy in endometrial cancer.
Reijnen C; Küsters-Vandevelde HVN; Prinsen CF; Massuger LFAG; Snijders MPML; Kommoss S; Brucker SY; Kwon JS; McAlpine JN; Pijnenborg JMA
Gynecol Oncol; 2019 Jul; 154(1):124-130. PubMed ID: 31103324
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy.
van den Heerik ASVM; Horeweg N; de Boer SM; Bosse T; Creutzberg CL
Int J Gynecol Cancer; 2021 Apr; 31(4):594-604. PubMed ID: 33082238
[TBL] [Abstract][Full Text] [Related]
8. Selecting Adjuvant Treatment for Endometrial Carcinoma Using Molecular Risk Factors.
Wortman BG; Nout RA; Bosse T; Creutzberg CL
Curr Oncol Rep; 2019 Jul; 21(9):83. PubMed ID: 31367798
[TBL] [Abstract][Full Text] [Related]
9. Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer.
Talhouk A; McConechy MK; Leung S; Yang W; Lum A; Senz J; Boyd N; Pike J; Anglesio M; Kwon JS; Karnezis AN; Huntsman DG; Gilks CB; McAlpine JN
Cancer; 2017 Mar; 123(5):802-813. PubMed ID: 28061006
[TBL] [Abstract][Full Text] [Related]
10. Association of p53 mutations and a codon 72 single nucleotide polymorphism with lower overall survival and responsiveness to adjuvant radiotherapy in endometrioid endometrial carcinomas.
Saffari B; Bernstein L; Hong DC; Sullivan-Halley J; Runnebaum IB; Grill HJ; Jones LA; El-Naggar A; Press MF
Int J Gynecol Cancer; 2005; 15(5):952-63. PubMed ID: 16174251
[TBL] [Abstract][Full Text] [Related]
11. [Histological and molecular classification of endometrial carcinoma and therapeutical implications].
Genestie C; Leary A; Devouassoux M; Auguste A
Bull Cancer; 2017 Dec; 104(12):1001-1012. PubMed ID: 29031505
[TBL] [Abstract][Full Text] [Related]
12. Endometrial Cancer: Transitioning from Histology to Genomics.
Mitric C; Bernardini MQ
Curr Oncol; 2022 Jan; 29(2):741-757. PubMed ID: 35200562
[TBL] [Abstract][Full Text] [Related]
13. Clonal evolution in paired endometrial intraepithelial neoplasia/atypical hyperplasia and endometrioid adenocarcinoma.
Russo M; Broach J; Sheldon K; Houser KR; Liu DJ; Kesterson J; Phaeton R; Hossler C; Hempel N; Baker M; Newell JM; Zaino R; Warrick JI
Hum Pathol; 2017 Sep; 67():69-77. PubMed ID: 28712776
[TBL] [Abstract][Full Text] [Related]
14. Molecular approaches for classifying endometrial carcinoma.
Piulats JM; Guerra E; Gil-Martín M; Roman-Canal B; Gatius S; Sanz-Pamplona R; Velasco A; Vidal A; Matias-Guiu X
Gynecol Oncol; 2017 Apr; 145(1):200-207. PubMed ID: 28040204
[TBL] [Abstract][Full Text] [Related]
15. Endometrial Carcinoma Diagnosis: Use of FIGO Grading and Genomic Subcategories in Clinical Practice: Recommendations of the International Society of Gynecological Pathologists.
Soslow RA; Tornos C; Park KJ; Malpica A; Matias-Guiu X; Oliva E; Parkash V; Carlson J; McCluggage WG; Gilks CB
Int J Gynecol Pathol; 2019 Jan; 38 Suppl 1(Iss 1 Suppl 1):S64-S74. PubMed ID: 30550484
[TBL] [Abstract][Full Text] [Related]
16. Molecular insights into the classification of high-grade endometrial carcinoma.
Hussein YR; Soslow RA
Pathology; 2018 Feb; 50(2):151-161. PubMed ID: 29246451
[TBL] [Abstract][Full Text] [Related]
17. Single-institutional outcomes of adjuvant brachytherapy for Stage I endometrial cancer-Are outcomes consistent with randomized studies?
Dohopolski MJ; Horne ZD; Gebhardt BJ; Glaser SM; Edwards RP; Kelley JL; Comerci JT; Olawaiye AB; Courtney-Brooks M; Berger JL; Sukumvanich P; Beriwal S
Brachytherapy; 2018; 17(3):564-570. PubMed ID: 29426745
[TBL] [Abstract][Full Text] [Related]
18. High-grade endometrial carcinomas: Morphologic spectrum and molecular classification.
Zhang C; Zheng W
Semin Diagn Pathol; 2022 May; 39(3):176-186. PubMed ID: 34852949
[TBL] [Abstract][Full Text] [Related]
19. Impact of different adjuvant radiotherapy modalities on women with early-stage intermediate- to high-risk endometrial cancer.
Jin M; Hou X; Sun X; Zhang Y; Hu K; Zhang F
Int J Gynecol Cancer; 2019 Oct; 29(8):1264-1270. PubMed ID: 31320487
[TBL] [Abstract][Full Text] [Related]
20. The impact of adjuvant vaginal brachytherapy in women with Stage II uterine endometrioid carcinoma: Results of a National Cancer Database analysis.
Lee JK; Ghanem AI; Modh A; Burmeister C; Mahmoud O; Maxwell GL; Elshaikh MA
Brachytherapy; 2018; 17(2):319-325. PubMed ID: 29174935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]